Patients with stage @B , @C , @B , and @C melanoma were randomly assigned to receive interferon alfa-@b ( IFN -- @b ) @ MIU/m ( @ ) intravenously ( IV ) daily @ days per week for @ weeks ( arm A ) versus the same regimen followed by IFN -- @b @ MIU/m ( @ ) administered subcutaneously three times per week for @ weeks ( arm B ) and observed for relapse-free survival ( RFS ) and overall survival .